Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Applied DNA Sciences Inc

Company price
None USD 0.00(0%)
Last update at 2026-01-08T21:03:18.651554Z
Market Cap
0.59M

Momentum Score

…

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.56
Low
37.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
5.52M
Revenue Per Share
7.67
Gross Profit TTM
5.05M
Debt / Equity
0.25
ROE
-252.30%
Net Debt
-5.91M
ROCE
-109.27%
Diluted EPS TTM
-17.63

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Income before tax -10.02M -8.27M -14.28M -13.03M -8.62M
Minority interest 0.08M 0.00M -0.01M -0.00M -0.01M
Net income -9.95M -8.38M -16.03M -12.76M -8.63M
Selling general administrative 12.75M 15.10M 12.61M 10.14M 10.28M
Gross profit 5.53M 5.05M 4.93M 1.21M 4.51M
Reconciled depreciation 1.36M 1.29M 0.84M 0.29M 0.39M
Ebit -11.81M -13.97M -12.29M -12.53M -9.12M
Ebitda -10.45M -21.38M -9.69M -12.63M -7.47M
Depreciation and amortization 1.36M -7.41M 2.60M -0.09M 1.65M
Non operating income net other - - - -0.38M -1.30M
Operating income -10.95M -13.97M -12.29M -12.53M -9.12M
Other operating expenses 24.32M 32.14M 21.32M 14.47M 14.51M
Interest expense - -13.22M 1.99M 0.12M 0.74M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.01M
Interest income 0.08M 0.01M - - 1.81M
Net interest income 0.08M 0.01M 0.01M -0.12M -0.16M
Income tax expense -0.08M 0.11M 1.75M -0.26M 0.01M
Total revenue 13.37M 18.17M 9.03M 1.93M 5.39M
Total operating expenses 16.49M 19.02M 17.22M 13.75M 13.64M
Cost of revenue 7.83M 13.12M 4.10M 0.72M 0.88M
Total other income expense net 0.86M 5.70M -1.99M -0.49M 0.51M
Net income from continuing ops -10.02M -8.27M -14.28M -13.03M -8.63M
Net income applicable to common shares - -8.38M -14.29M -13.03M -8.93M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Total assets 13.65M 22.27M 14.42M 11.34M 3.56M
Intangible assets 2.70M - - 0.61M 0.73M
Other current assets 0.39M 1.06M 0.57M 0.60M 0.60M
Total liab 8.78M 9.36M 3.30M 5.63M 4.41M
Total stockholder equity 4.95M 12.91M 11.11M 5.72M -0.84M
Deferred long term liab - - - - 0.11M
Other current liab 1.20M 1.88M 0.98M 0.68M 0.46M
Common stock 0.01M 0.01M 0.01M 0.01M 0.00M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.00M
Retained earnings -302.45M -292.50M -284.12M -269.84M -256.81M
Other liab - 5.17M 0.03M 0.85M 0.62M
Good will - - - 0.29M 0.29M
Other assets - 0.10M 0.10M 0.10M 0.17M
Cash 7.15M 15.22M 6.55M 7.79M 0.56M
Total current liabilities 2.85M 4.19M 3.27M 4.27M 2.25M
Current deferred revenue 0.08M 0.56M 0.28M 0.51M 0.63M
Net debt -5.91M -15.22M -6.55M -5.44M 0.99M
Short term debt 0.50M - - 1.83M -
Short long term debt - - - 1.83M -
Short long term debt total 1.24M - - 2.35M 1.55M
Other stockholder equity 307.38M 305.40M 295.23M 275.55M 255.96M
Property plant equipment - 2.22M 3.02M 1.28M 0.23M
Total current assets 8.13M 19.94M 11.30M 9.08M 2.15M
Net tangible assets - 12.91M 11.11M 4.83M -1.86M
Net receivables 0.26M 3.07M 2.80M 0.19M 0.84M
Long term debt - - - 0.52M 1.44M
Inventory 0.33M 0.60M 1.37M 0.50M 0.14M
Accounts payable 1.07M 1.74M 2.01M 1.25M 1.15M
Noncontrolling interest in consolidated entity - - - -0.01M -0.01M
Accumulated other comprehensive income - - - -2.45M -2.29M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -269.84M -256.81M
Non currrent assets other 0.75M 0.10M 0.10M 0.10M 0.17M
Deferred long term asset charges - - - - 0.11M
Non current assets total 5.53M 2.32M 3.12M 2.26M 1.42M
Capital lease obligations 1.24M - - - -
Long term debt total - - - 0.52M 1.44M
Breakdown 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Type yearly yearly yearly yearly yearly
Date 2023-09-30 2022-09-30 2021-09-30 2020-09-30 2019-09-30
Investments -1.10M -0.49M -2.55M -1.06M -0.07M
Change to liabilities - 1.21M -0.14M 0.43M 0.67M
Total cashflows from investing activities - -0.49M -2.55M -1.06M -0.07M
Net borrowings - - -1.67M 0.85M 1.99M
Total cash from financing activities 0.95M 18.13M 14.70M 19.43M 5.83M
Change to operating activities - -0.49M 0.03M -0.03M 0.02M
Net income -10.02M -8.27M -14.28M -13.03M -8.63M
Change in cash -7.31M 8.66M -1.23M 7.23M -1.10M
Begin period cash flow 15.22M 6.55M 7.79M 0.56M 1.66M
End period cash flow 7.90M 15.22M 6.55M 7.79M 0.56M
Total cash from operating activities -6.22M -8.98M -13.39M -11.14M -6.86M
Issuance of capital stock 0.00M 14.43M 13.76M 10.64M 2.87M
Depreciation 1.36M 1.29M 0.84M 0.29M 0.39M
Dividends paid - -0.11M - 0.00M -
Change to inventory 0.27M 0.77M -0.87M -0.35M 0.08M
Change to account receivables 3.05M -0.53M -2.64M 0.60M 0.64M
Sale purchase of stock 0.95M - - 18.70M 3.85M
Other cashflows from financing activities -0.95M 3.81M 2.61M 8.90M 2.96M
Change to netincome - -2.95M 3.67M 1.05M 2.65M
Capital expenditures 0.08M 0.49M 2.55M 1.06M 0.07M
Change receivables - - - 0.60M 0.64M
Cash flows other operating - - - -0.15M -2.68M
Cash and cash equivalents changes - - - 7.23M -1.10M
Change in working capital 2.45M 0.95M -3.62M 0.53M 0.68M
Stock based compensation 1.03M 2.52M 1.67M 1.00M 1.13M
Other non cash items -1.72M -5.47M 1.99M 0.03M -1.70M
Free cash flow -6.30M -9.47M -15.94M -12.21M -6.93M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TMO
Thermo Fisher Scientific Inc
-17.51
2.54%
671.24 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation
-0.25
0.11%
220.36 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd
-
-%
23.77 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd
-0.92
3.87%
22.85 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Applied DNA Sciences Inc

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

50 Health Sciences Drive, Stony Brook, NY, United States, 11790

631 240 8800

52

Name Title Year Born
Dr. James A. Hayward Ph.D., Sc.D. Chairman, Pres & CEO 1954
Ms. Beth M. Jantzen CPA, CPA Chief Financial Officer 1976
Ms. Judith Murrah COO & Sec. 1958
Mr. Sanjay M. Hurry Exec. Director of Investor Relations & Corp. Communications NA
Mr. Clay Shorrock Esq., J.D. Chief Legal Officer & Exec. Director of Bus. Devel. 1985
Mr. John Shearman Exec. Director of Marketing & Cannabis Bus. NA
Mr. Tony Benson Managing Director of EMEA NA
Ms. Janice Meraglia VP, Gov. & Military Programs NA
Ms. MeiLin Wan VP of Textile Sales NA
Dr. Stephen Hughes Director of DNA Programs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…